Geisinger Health System announced that 150,000 participants have signed up for its comprehensive biobank and DNA sequencing study, known as the “MyCode Community Health Initiative.” The U.S. Centers for Disease Control and Prevention estimates that nearly 2 million people in the U.S. are at an increased risk for adverse health outcomes because they have genetic mutations that predispose them to one of the following conditions: hereditary breast and ovarian cancer syndrome, Lynch syndrome, and hereditary high cholesterol. These are three conditions among a total of 27 that Geisinger informs MyCode participants about as a result of the nation’s largest genomic sequencing study. MyCode analyzes the DNA of patient participants to help improve healthcare delivery. The study aims to find ways to diagnose certain conditions earlier and to develop new treatments or management strategies. The goal is to give every Geisinger patient the opportunity to participate in the study.